Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
Defina M, Lazzarotto D, Guolo F, Minetto P, Fracchiolla NS, Giglio F, Forghieri F, Vitale A, Chiaretti S, Papayannidis C, Piccini M, Mulè A, Bocchia M, Leoncin M, Gurrieri C, Aprile L, Lunghi M, Bonifacio M, Pasciolla C, Cerrano M, Fumagalli M, Foà R, Candoni A. Defina M, et al. Among authors: fumagalli m. Leuk Res. 2022 Nov;122:106963. doi: 10.1016/j.leukres.2022.106963. Epub 2022 Sep 21. Leuk Res. 2022. PMID: 36155352 No abstract available.
Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.
Bassan R, Fumagalli M, Chiaretti S, Audisio E, Cascavilla N, Paolini S, Delia M, Cerqui E, Micò C, Fabbiano F, Canichella M, Scattolin AM, Perfetti P, Paoloni F, Iodice M, Vitale A, Della Starza I, Fazi P, Vignetti M, Foà R. Bassan R, et al. Among authors: fumagalli m. Leuk Lymphoma. 2019 Dec;60(14):3482-3492. doi: 10.1080/10428194.2019.1639170. Epub 2019 Jul 12. Leuk Lymphoma. 2019. PMID: 31298059 Clinical Trial.
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
Bocchia M, Candoni A, Borlenghi E, Defina M, Filì C, Cattaneo C, Sammartano V, Fanin R, Sciumè M, Sicuranza A, Imbergamo S, Riva M, Fracchiolla N, Latagliata R, Caizzi E, Mazziotta F, Alunni G, Di Bona E, Crugnola M, Rossi M, Consoli U, Fontanelli G, Greco G, Nadali G, Rotondo F, Todisco E, Bigazzi C, Capochiani E, Molteni A, Bernardi M, Fumagalli M, Rondoni M, Scappini B, Ermacora A, Simonetti F, Gottardi M, Lambertenghi Deliliers D, Michieli M, Basilico C, Galeone C, Pelucchi C, Rossi G. Bocchia M, et al. Among authors: fumagalli m. Hematol Oncol. 2019 Oct;37(4):447-455. doi: 10.1002/hon.2663. Epub 2019 Aug 20. Hematol Oncol. 2019. PMID: 31385337
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07.
Bassan R, Pavoni C, Intermesoli T, Spinelli O, Tosi M, Audisio E, Marmont F, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Fumagalli M, Mattei D, Romani C, Cortelezzi A, Fracchiolla N, Ciceri F, Bernardi M, Scattolin AM, Depaoli L, Masciulli A, Oldani E, Rambaldi A. Bassan R, et al. Among authors: fumagalli m. Blood Cancer J. 2020 Nov 13;10(11):119. doi: 10.1038/s41408-020-00383-2. Blood Cancer J. 2020. PMID: 33188164 Free PMC article. Clinical Trial.
Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy.
Efficace F, Platzbecker U, Breccia M, Cottone F, Carluccio P, Salutari P, Di Bona E, Borlenghi E, Autore F, Levato L, Finizio O, Mancini V, D'Ardia S, Schlenk RF, Melillo L, Fumagalli M, Fiedler W, Beltrami G, Fracchiolla NS, Bernardi M, Fazi P, Annibali O, Mayer K, Voso MT, Vignetti M. Efficace F, et al. Among authors: fumagalli m. Blood Adv. 2021 Nov 9;5(21):4370-4379. doi: 10.1182/bloodadvances.2021004649. Blood Adv. 2021. PMID: 34529768 Free PMC article. Clinical Trial.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G; AVALON Cooperative Group. Todisco E, et al. Among authors: fumagalli m. Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608. Epub 2023 Jan 24. Cancer. 2023. PMID: 36692409 Free article.
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination-Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda.
Rossi G, Borlenghi E, Zappasodi P, Lussana F, Bernardi M, Basilico C, Molteni A, Lotesoriere I, Turrini M, Frigeni M, Fumagalli M, Cozzi P, Gigli F, Cattaneo C, Fracchiolla NS, Riva M, Martini G, Mancini V, Cairoli R, Todisco E. Rossi G, et al. Among authors: fumagalli m. Cancers (Basel). 2024 Jan 16;16(2):386. doi: 10.3390/cancers16020386. Cancers (Basel). 2024. PMID: 38254875 Free PMC article.
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Zappasodi P, Marbello L, Borlenghi E, Fumagalli M, Bernardi M, Fracchiolla N, Mancini V, Da Vià M, Ravano E, Cerqui E, Ferretti VV, Rocca B, Calvello C, Cazzola M, Castagnola C, Rossi G. Zappasodi P, et al. Among authors: fumagalli m. Ann Hematol. 2018 Nov;97(11):2107-2115. doi: 10.1007/s00277-018-3424-4. Epub 2018 Jul 15. Ann Hematol. 2018. PMID: 30009341 Clinical Trial.
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, Cerchione C, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G. Ghelli Luserna Di Rorà A, et al. Among authors: fumagalli m. Cell Biol Toxicol. 2023 Jun;39(3):795-811. doi: 10.1007/s10565-021-09640-x. Epub 2021 Sep 14. Cell Biol Toxicol. 2023. PMID: 34519926 Free PMC article.
618 results